| Primary |
| Drug Use For Unknown Indication |
85.8% |
| Atrial Fibrillation |
2.4% |
| Cardiac Failure |
1.7% |
| Hypertension |
1.5% |
| Myocardial Infarction |
1.3% |
| Prophylaxis |
1.3% |
| Diabetes Mellitus |
1.0% |
| Depression |
0.6% |
| Asthma |
0.4% |
| Essential Hypertension |
0.4% |
| Fasciitis |
0.4% |
| Gout |
0.4% |
| Hypothyroidism |
0.4% |
| Insomnia |
0.4% |
| Rheumatoid Arthritis |
0.4% |
| Sepsis |
0.4% |
| Type 2 Diabetes Mellitus |
0.4% |
| Anaemia |
0.3% |
| Angina Pectoris |
0.3% |
| Arrhythmia |
0.3% |
|
| Renal Failure Acute |
29.4% |
| Renal Failure |
11.8% |
| Toxic Epidermal Necrolysis |
5.9% |
| Fall |
4.9% |
| Vomiting |
4.9% |
| Hyponatraemia |
3.9% |
| Malaise |
3.9% |
| Rash Pustular |
3.9% |
| Stevens-johnson Syndrome |
3.9% |
| Pulmonary Arterial Hypertension |
2.9% |
| Renal Tubular Necrosis |
2.9% |
| Somnolence |
2.9% |
| Thrombocytopenia |
2.9% |
| Tumour Lysis Syndrome |
2.9% |
| Weight Increased |
2.9% |
| Acute Pulmonary Oedema |
2.0% |
| Convulsion |
2.0% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.0% |
| Haematoma |
2.0% |
| Heparin-induced Thrombocytopenia |
2.0% |
|
| Secondary |
| Product Used For Unknown Indication |
44.2% |
| Drug Use For Unknown Indication |
24.7% |
| Hypertension |
5.5% |
| Cardiac Failure |
3.6% |
| Diabetes Mellitus |
2.9% |
| Prophylaxis |
2.3% |
| Type 2 Diabetes Mellitus |
2.3% |
| Atrial Fibrillation |
1.9% |
| Essential Hypertension |
1.9% |
| Suicide Attempt |
1.9% |
| Oedema |
1.6% |
| Diuretic Therapy |
1.3% |
| Device Related Infection |
1.0% |
| Infection |
1.0% |
| Angina Pectoris |
0.6% |
| Bronchitis |
0.6% |
| Deep Vein Thrombosis |
0.6% |
| Depression |
0.6% |
| Depressive Symptom |
0.6% |
| Hypokalaemia |
0.6% |
|
| Renal Failure Acute |
18.8% |
| Renal Failure |
8.3% |
| Weight Decreased |
8.3% |
| Hyponatraemia |
6.3% |
| Rhabdomyolysis |
6.3% |
| Toxic Epidermal Necrolysis |
6.3% |
| Eczema |
4.2% |
| Sepsis |
4.2% |
| Somnolence |
4.2% |
| Superinfection |
4.2% |
| Thrombocytopenia |
4.2% |
| Tricuspid Valve Incompetence |
4.2% |
| Vascular Calcification |
4.2% |
| Vasculitis |
4.2% |
| Fall |
2.1% |
| General Physical Health Deterioration |
2.1% |
| Heparin-induced Thrombocytopenia |
2.1% |
| Oedema |
2.1% |
| Osteonecrosis |
2.1% |
| Pancreatitis Acute |
2.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
29.0% |
| Drug Use For Unknown Indication |
26.3% |
| Hypertension |
6.2% |
| Diabetes Mellitus |
4.4% |
| Type 2 Diabetes Mellitus |
4.4% |
| Plasma Cell Myeloma |
3.7% |
| Mantle Cell Lymphoma |
3.5% |
| Cardiac Failure |
2.8% |
| Pulmonary Arterial Hypertension |
2.7% |
| Prophylaxis |
2.1% |
| Insulin-requiring Type Ii Diabetes Mellitus |
1.9% |
| Multiple Myeloma |
1.8% |
| Pain |
1.8% |
| Oedema |
1.6% |
| Rheumatoid Arthritis |
1.6% |
| Arrhythmia |
1.4% |
| Coronary Artery Bypass |
1.4% |
| Anaemia |
1.2% |
| Accidental Exposure |
1.1% |
| Acute Pulmonary Oedema |
1.1% |
|
| Renal Failure Acute |
15.9% |
| Hypoglycaemia |
8.5% |
| Thrombocytopenia |
8.5% |
| Renal Failure |
6.1% |
| Vomiting |
6.1% |
| Cardiac Failure |
4.9% |
| Weight Decreased |
4.9% |
| Acute Generalised Exanthematous Pustulosis |
3.7% |
| Cerebellar Syndrome |
3.7% |
| Death |
3.7% |
| Hepatitis Cholestatic |
3.7% |
| Oedema Peripheral |
3.7% |
| Pruritus |
3.7% |
| Pyrexia |
3.7% |
| Respiratory Failure |
3.7% |
| Somnolence |
3.7% |
| Urinary Retention |
3.7% |
| Vomiting Projectile |
3.7% |
| Bronchopneumonia |
2.4% |
| Carbon Monoxide Diffusing Capacity Decreased |
2.4% |
|
| Interacting |
|
| Hypotension |
66.7% |
| Urinary Tract Infection |
33.3% |
|
